Asian press release distribution

Press Releases for Monday, December 2, 2024

#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions 22:50 HKT/SGT

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia 22:30 HKT/SGT

Honda Introduces AI-powered Social Robot, Haru, to University Hospital in Spain 22:08 HKT/SGT

MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO 22:00 HKT/SGT

DENSO to Exhibit at "Automechanika Dubai 2024" 21:38 HKT/SGT

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia 21:30 HKT/SGT

Fujitsu expands global strategic collaboration agreement with AWS to promote customer digital transformation across industries 21:07 HKT/SGT

MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO 21:00 HKT/SGT

康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利 20:49 HKT/SGT

康哲药业获得治疗痛风及高尿酸血症的1类新药独家商业化权利 20:37 HKT/SGT

三菱重工、マカオLRT「石排湾」および「横琴」の両延伸線が営業運転を開始 16:30 HKT/SGT

CleverTap Report: 46% of Product Managers Cite Resource Limitations as Top Barrier to App and Web Experimentation 16:30 HKT/SGT

富士通、AWSとのグローバルな戦略的協業契約を拡大し、お客様のデジタルトランスフォーメーションを加速 13:30 HKT/SGT

最新のAIによる⽇本株の銘柄スクリーニングアプリ『AI銘柄スクリーナー』の無料β版をリリース 12:15 HKT/SGT

MHI Receives Order to Supply 24 MOX Fuel Assemblies for Unit 3 of Ikata Nuclear Power Station, Shikoku Electric Power Co. Inc. 11:55 HKT/SGT

MHI Receives Order from Taiwan High Speed Rail Corporation for Trackwork and Core System for New Rolling Stock Inspection Shop in Zuoying Depot 11:21 HKT/SGT

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong 10:34 HKT/SGT

雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德（VELSIPITY(R)） 10:30 HKT/SGT

云顶新耀宣布中国香港卫生署正式受理伊曲莫德（VELSIPITY(R)） 10:25 HKT/SGT

ULVAC Launches New Deposition System for Semiconductor Applications: Model "ENTRON-EXX" 08:10 HKT/SGT

ACN Search:

Andy Pitre, EVP of Product, HubSpot, launching Breeze at INBOUND 2024


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575